Noopur S. Raje, MD, is Professor of Medicine at Harvard Medical School, the director of the Center for Multiple Myeloma, and the Rita Kelley Chair in Oncology at Massachusetts General Hospital Cancer Center in Boston, MA, USA. She studied medicine at B.J. Medical College, Pune University, India, and trained in internal medicine at Massachusetts General Hospital. This was followed by a fellowship in hematology/oncology at the Dana-Farber Cancer Institute, Boston.
Dr. Raje’s research focuses primarily on developing novel therapeutic strategies for the treatment of multiple myeloma and related plasma cell disorders. Her laboratory efforts are aimed at identifying cellular signaling pathways that contribute to the survival and proliferation of myeloma cells in the bone environment. Stemming from these studies, she has developed and led clinical trials to specifically harness these pathways. Her expertise in cellular therapies has led to FDA approval of the first in class CAR T cell product, Ide-cel in myeloma. Her work related to myeloma bone disease has resulted in FDA approval of the first in class RANK ligand antibody, denosumab.
Professor Raje is co-chair of the National Cancer Institute Myeloma Steering Committee, co-chair of the Educationa Committee of the International Myeloma Society, a member of the International Myeloma Working Group, and serves on educational committees for ASCO and ASH. She has received several awards and has published widely on multiple myeloma.
Director, Center for Multiple Myeloma, Mass General Cancer Center;
Professor of Medicine, HMS
Join our email list to receive exclusive offers